{"id":"NCT00122317","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)","officialTitle":"Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2008-09","completion":"2008-10","firstPosted":"2005-07-22","resultsPosted":"2017-06-05","lastUpdate":"2018-03-13"},"enrollment":187,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Hemoglobinuria, Nocturnal"],"interventions":[{"type":"DRUG","name":"eculizumab","otherNames":["Soliris"]}],"arms":[{"label":"Eculizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.","primaryOutcome":{"measure":"Incidence of Treatment-emergent Adverse Events","timeFrame":"From time of consent to a maximum of 2.5 years of study treatment","effectByArm":[{"arm":"Eculizumab","deltaMin":182,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":40,"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["17702897"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":187},"commonTop":["Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Diarrhoea","Nausea"]}}